🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareNovo Nordisk CagriSema Phase 3 results — need advice Page 5

Novo Nordisk CagriSema Phase 3 results — need advice

mike_mod Tue, Nov 18, 2025 at 8:31 PM 43 replies 1,982 viewsPage 5 of 9
AmyNC_wife
Member
634
2,890
Jun 2024
North Carolina
Nov 21, 2025 at 10:51 PM#21
Dr.MetabolicMD said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

Adding the part of the answer the thread has not reached. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

Last edited: Nov 21, 2025 at 11:51 PM
24 24JessicaM_2024, TomFromTexas, mike.trainer_LA and 21 others
Reply Quote Save Share Report
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Nov 22, 2025 at 8:31 PM#22

The figures, for anyone assembling their own picture. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

23 23MikeFit_NJ, InsuranceTom, WendyG_ATL and 20 others
Reply Quote Save Share Report
SurmountFan_IN
Member
789
3,456
May 2024
Indianapolis, IN
Nov 23, 2025 at 6:12 PM#23

One thing that is still open after Dr.MetabolicMD’s answer:

What did you change at the same time, and can you separate the two now?

22 22traveltech_sara, AttorneyGrant, DebRD_ATL and 19 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Nov 24, 2025 at 3:53 PM#24
NicoleRaleigh said:
If you are going to change something, change one thing and give it long enough to express itself.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.

Last edited: Nov 24, 2025 at 6:53 PM
21 21Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 18 others
Reply Quote Save Share Report
maya_sedona
Member
289
1,234
Sep 2024
Sedona, AZ
Nov 25, 2025 at 1:35 PM#25
NicoleRaleigh said:
If you are going to change something, change one thing and give it long enough to express itself.

Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.

20 20Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 17 others
Reply Quote Save Share Report
1345679

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register